Skip to main content
SLU publication database (SLUpub)
Research article - Peer-reviewed, 2008

Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome

Xue, Yuan; Religa, Piotr; Cao, Renhai; Hansen, Anker Jon; Lucchini, Franco; Jones, Bernt; Wu, Yan; Zhu, Zhenping; Pytowski, Bronislaw; Liang, Yuxiang; Zhong, Weide; Vezzoni, Paolo; Rozell, Bjoern; Cao, Yihai

Abstract

The underlying mechanism by which anti-VEGF agents prolong cancer patient survival is poorly understood. We show that in a mouse tumor model, VEGF systemically impairs functions of multiple organs including those in the hematopoietic and endocrine systems, leading to early death. Anti-VEGF antibody, bevacizumab, and anti-VEGF receptor 2 (VEGFR-2), but not anti-VEGFR-1, reversed VEGF-induced cancer-associated systemic syndrome (CASS) and prevented death in tumor-bearing mice. Surprisingly, VIEGFR2 blockage improved survival by rescuing mice from CASS without significantly compromising tumor growth, suggesting that "off-tumor" VEGF targets are more sensitive than the tumor vasculature to anti-VEGF drugs. Similarly, VEGF-induced CASS occurred in a spontaneous breast cancer mouse model over-expressing neu. Clinically, VEGF expression and CASS severity positively correlated in various human cancers. These findings define novel therapeutic targets of anti-VEGF agents and provide mechanistic insights into the action of this new class of clinically available anti-VEGF cancer drugs.

Keywords

angiogenesis; antiangiogenic therapy; cancer syndrome; tumor growth; VEGF

Published in

Proceedings of the National Academy of Sciences
2008, Volume: 105, number: 47, pages: 18513-18518
Publisher: NATL ACAD SCIENCES

    Sustainable Development Goals

    SDG3 Good health and well-being

    UKÄ Subject classification

    Cancer and Oncology

    Publication identifier

    DOI: https://doi.org/10.1073/pnas.0807967105

    Permanent link to this page (URI)

    https://res.slu.se/id/publ/26144